Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SAR444245 plus Cemiplimab in HPV-related Oropharynx Cancer
NCT05535023Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of pegenzileukin in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Aug 2022; status: withdrawn.
02
Drugs
pegenzileukin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05535023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535023.